Highlight

Thank you for visiting our website. We hope you'll find all information you need. Please contact us if you have any questions. We will be happy to answer them. 

External validation antiplatelet CE-analysis:

"Robust methodology and valid conclusions"

The UK NHS Centre for Reviews and Dissemination assessed Pharmerit's cost-effectiveness analysis: "Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective." The Centre concluded that this economic evaluation was based on a robust methodology and that the authors’ conclusions were valid and appropriate. The assessment is publically available in the NHS Economic Evaluation Database (NHS EED).


,

Pharmerit's research published in Sleep

Pharmerit is pleased to announce that its research into insomnia has been published in Sleep. The manuscript quantifies the health economic consequences of treating adult patients with primary chronic insomnia with Eszopiclone or placebo. The analysis was conducted using a health economic model based on patient-level data, combined with data from a claims database and published literature. (link to abstract)


,

iHEA Congress, July 12-15, Beijing, China

Pharmerit staff members will participate in the 2009 International Health Economics Association (iHEA) Congress in Beijing. Our colleague Stephanie Thurston will be delivering a short format presentation titled: “Too Much Information? Using Priors from Published Meta-Analyses to Inform a Cost-Effectiveness Model of Intensive-Dose Statin Therapy in Acute Coronary Syndrome Patients”. This podium presentation is part of a cost-effectiveness analysis session at the congress. 


,

News

Publications

nieuwsviewerText_internetNieuws757No newsitems available...nieuwsviewerText_internetPublicaties754No publications available...